Biogen (BIIB) Asset Utilization Ratio (2009 - 2026)
Biogen (BIIB) recorded quarterly Asset Utilization Ratio of 0.34 in Q1 2026, little changed quarter-over-quarter from 0.34 in Q4 2025, and down 3.65% on a YoY basis from 0.35 in Q1 2025.
Biogen (BIIB) Asset Utilization Ratio (2009 - 2026) Analysis & Trends
Biogen's Asset Utilization Ratio history runs 18 years deep, the most recent figure standing at 0.34 for Q1 2026.
- In Q1 2026, Asset Utilization Ratio fell 3.65% year-over-year to 0.34; the TTM figure through Mar 2026 stood at 0.34 (down 3.65% YoY), while the FY2025 annual figure was 0.34, down 2.39% from the prior year.
- Asset Utilization Ratio was 0.34 for Q1 2026 at Biogen, roughly flat from 0.34 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.46 in Q1 2022 to a low of 0.34 in Q4 2025.
- Historically, Asset Utilization Ratio has averaged 0.38 across 5 years, with a median of 0.36 in 2024.
- The sharpest annual moves came in 2023 and 2025: Asset Utilization Ratio slipped 13.21% in 2023, then climbed 0.36% in 2025.
- A 5-year view of Asset Utilization Ratio shows it stood at 0.41 in 2022, then fell by 13.21% to 0.36 in 2023, then declined by 3.94% to 0.34 in 2024, then retreated by 1.76% to 0.34 in 2025, then gained by 0.0% to 0.34 in 2026.
- The last three Asset Utilization Ratio figures came in at 0.34 (Q1 2026), 0.34 (Q4 2025), and 0.35 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 0.53 |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 0.63 |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 0.48 |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 0.46 |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 0.50 |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 0.41 |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 0.52 |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 0.12 |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 0.55 |
| 10 | Biogen | 28.75 Bn | 24.47 Bn | 1.82 Bn | 0.34 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.34 |
| Dec 31, 2025 | 0.34 |
| Sep 30, 2025 | 0.35 |
| Jun 30, 2025 | 0.35 |
| Mar 31, 2025 | 0.35 |
| Dec 31, 2024 | 0.34 |
| Sep 30, 2024 | 0.35 |
| Jun 30, 2024 | 0.36 |
| Mar 31, 2024 | 0.36 |
| Dec 31, 2023 | 0.36 |
| Sep 30, 2023 | 0.37 |
| Jun 30, 2023 | 0.40 |
| Mar 31, 2023 | 0.41 |
| Dec 31, 2022 | 0.41 |
| Sep 30, 2022 | 0.42 |
| Jun 30, 2022 | 0.44 |
| Mar 31, 2022 | 0.46 |
| Dec 31, 2021 | 0.46 |
| Sep 30, 2021 | 0.46 |
| Jun 30, 2021 | 0.48 |